Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
dc.contributor.author | Miles, D. | |
dc.contributor.author | Chan, Arlene | |
dc.contributor.author | Dirix, L. | |
dc.contributor.author | Cortés, J. | |
dc.contributor.author | Pivot, X. | |
dc.contributor.author | Tomczak, P. | |
dc.contributor.author | Delozier, T. | |
dc.contributor.author | Sohn, J. | |
dc.contributor.author | Provencher, L. | |
dc.contributor.author | Puglisi, F. | |
dc.contributor.author | Harbeck, N. | |
dc.contributor.author | Steger, G. | |
dc.contributor.author | Schneeweiss, A. | |
dc.contributor.author | Wardley, A. | |
dc.contributor.author | Chlistalla, A. | |
dc.contributor.author | Romieu, G. | |
dc.date.accessioned | 2017-01-30T10:50:49Z | |
dc.date.available | 2017-01-30T10:50:49Z | |
dc.date.created | 2014-11-19T01:13:19Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | Miles, D. and Chan, A. and Dirix, L. and Cortés, J. and Pivot, X. and Tomczak, P. and Delozier, T. et al. 2010. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology. 28 (20): pp. 3239-3247. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/6136 | |
dc.publisher | American Society of Clinical Oncology | |
dc.title | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | |
dc.type | Journal Article | |
dcterms.source.volume | 28 | |
dcterms.source.number | 20 | |
dcterms.source.startPage | 3239 | |
dcterms.source.endPage | 3247 | |
dcterms.source.issn | 0732 183X | |
dcterms.source.title | Journal of Clinical Oncology | |
curtin.accessStatus | Fulltext not available |